| 1 |
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Frank Stephen Hodi et al. · New England Journal of Medicine
Open access |
5 Jun 2010 |
15,337 |
| 2 |
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham, William Allum, Sally Patricia Stenning et al. · New England Journal of Medicine
|
6 Jul 2006 |
6,432 |
| 3 |
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al. · New England Journal of Medicine
Open access |
19 Apr 2015 |
5,968 |
| 4 |
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan W. Valle, Harpreet Singh Wasan, Daniel H. Palmer et al. · New England Journal of Medicine
Open access |
7 Apr 2010 |
4,489 |
| 5 |
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
3,488 |
| 6 |
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Alice Tsang Shaw et al. · New England Journal of Medicine
Open access |
Jun 2013 |
3,429 |
| 7 |
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine
Open access |
4 Jun 2017 |
3,322 |
| 8 |
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al. · New England Journal of Medicine
Open access |
16 Nov 2014 |
2,718 |
| 9 |
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al. · The Lancet Oncology
|
23 Mar 2015 |
2,696 |
| 10 |
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology
Open access |
Sep 2016 |
2,650 |
| 11 |
Pancreatic cancer
Jonathan D. Mizrahi, Rishi Surana, Juan W. Valle et al. · The Lancet
|
Jun 2020 |
2,586 |
| 12 |
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine
|
9 Feb 2011 |
2,567 |
| 13 |
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales et al. · Nature Reviews Gastroenterology & Hepatology
ReviewOpen access |
30 Jun 2020 |
2,543 |
| 14 |
Tracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal‐Hanjani et al. · New England Journal of Medicine
Open access |
26 Apr 2017 |
2,501 |
| 15 |
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Anthony Howell, Jack M. Cuzick, Michael Baum et al. · The Lancet
|
2005 |
2,295 |
| 16 |
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A.E. Cross et al. · Cancer Discovery
Open access |
4 Jun 2014 |
2,276 |
| 17 |
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo et al. · New England Journal of Medicine
Open access |
28 Oct 2015 |
2,220 |
| 18 |
Pathogenesis and clinical features of psoriasis
Christopher E.M. Griffiths, Jonathan NWN Barker · The Lancet
|
Jul 2007 |
2,164 |
| 19 |
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi Antero Janne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine
Open access |
29 Apr 2015 |
2,135 |
| 20 |
Conditions controlling the proliferation of haemopoietic stem cells in vitro
T. M. Dexter, Terence Allen, L. G. Lajtha · Journal of Cellular Physiology
|
Jun 1977 |
2,117 |
| 21 |
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Nick Thatcher, Alex Y. Chang, Purvish Mahendra Parikh et al. · The Lancet
|
Oct 2005 |
2,097 |
| 22 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas David James et al. · The Lancet
Open access |
21 Dec 2015 |
1,985 |
| 23 |
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al. · Nature
Open access104 authors |
25 Apr 2017 |
1,978 |
| 24 |
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al. · The Lancet
Open access |
24 Jan 2017 |
1,953 |
| 25 |
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
21 Aug 2013 |
1,936 |
| 26 |
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont et al. · New England Journal of Medicine
Open access |
15 Apr 2018 |
1,906 |
| 27 |
Ovarian cancer
Gordon C. Jayson, Elise C. Kohn, Henry Charles Kitchener et al. · The Lancet
|
21 Apr 2014 |
1,893 |
| 28 |
Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt
Christopher S. Potten, Markus W. Loeffler · Development
|
Dec 1990 |
1,818 |
| 29 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas David James et al. · New England Journal of Medicine
Open access |
3 Jun 2017 |
1,806 |
| 30 |
The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid
Okezie I. Aruoma, Barry B. Halliwell, Brigid M. Hoey et al. · Free Radical Biology and Medicine
|
1989 |
1,780 |
| 31 |
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
R. Charles Coombes et al. · New England Journal of Medicine
Open access |
10 Mar 2004 |
1,773 |
| 32 |
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert Louis Coleman et al. · The Lancet
Open access117 authors |
12 Sep 2017 |
1,729 |
| 33 |
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
Christopher M. Nutting, James P. Morden, Kevin Joseph Harrington et al. · The Lancet Oncology
Open access |
14 Jan 2011 |
1,721 |
| 34 |
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al. · New England Journal of Medicine
Open access |
19 Jun 2013 |
1,710 |
| 35 |
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
Andrew G. Renehan, Marcel Zwahlen, Christoph Erwin Minder et al. · The Lancet
Review |
Apr 2004 |
1,702 |
| 36 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun et al. · The Lancet
Open access |
Aug 2021 |
1,679 |
| 37 |
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew N.J. Tutt, Mark E. Robson, Judy Ellen Garber et al. · The Lancet
|
Jul 2010 |
1,660 |
| 38 |
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd et al. · New England Journal of Medicine
Open access |
31 May 2014 |
1,649 |
| 39 |
Small-cell lung cancer
Charles M. Rudin, Elisabeth M. Brambilla, Corinne Faivre Finn et al. · Nature Reviews Disease Primers
ReviewOpen access |
14 Jan 2021 |
1,632 |
| 40 |
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al. · The Lancet
|
2007 |
1,521 |
| 41 |
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz et al. · New England Journal of Medicine
Open access |
30 Sep 2019 |
1,500 |
| 42 |
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
Joanne Haviland, John R. Owen, John A. Dewar et al. · The Lancet Oncology
Open access |
18 Sep 2013 |
1,479 |
| 43 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al. · The Lancet
Open access |
21 Nov 2012 |
1,428 |
| 44 |
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
John P. Neoptolemos et al. · JAMA
|
7 Sep 2010 |
1,403 |
| 45 |
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
David R. Spigel et al. · Journal of Clinical Oncology
Open access |
2 Feb 2022 |
1,400 |
| 46 |
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Paul Dearnaley et al. · The Lancet Oncology
Open access |
22 Jun 2016 |
1,350 |
| 47 |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al. · The Lancet
Open access158 authors |
4 Jun 2018 |
1,338 |
| 48 |
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
D. Gareth Evans, M E Baser, J McGaughran et al. · Journal of Medical Genetics
Open access |
May 2002 |
1,297 |
| 49 |
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher Parker et al. · The Lancet
Open access |
21 Oct 2018 |
1,289 |
| 50 |
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al. · The Lancet
Open access |
17 Dec 2015 |
1,288 |